Geron (GERN) Expected to Announce Quarterly Earnings on Wednesday

Geron (NASDAQ:GERN - Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $45.29 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Geron Stock Down 2.1 %

Shares of GERN stock traded down $0.06 during trading hours on Friday, hitting $2.58. 8,953,523 shares of the company were exchanged, compared to its average volume of 11,789,030. The business has a 50 day moving average of $3.13 and a two-hundred day moving average of $3.88. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. Geron has a 52 week low of $1.64 and a 52 week high of $5.34. The company has a market capitalization of $1.56 billion, a PE ratio of -8.05 and a beta of 0.53.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on GERN shares. Needham & Company LLC increased their price objective on shares of Geron from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. B. Riley lowered their price objective on shares of Geron from $5.50 to $3.50 and set a "buy" rating for the company in a research report on Tuesday. Barclays upgraded shares of Geron to a "strong-buy" rating in a report on Friday, November 29th. Finally, HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Geron in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Geron has a consensus rating of "Moderate Buy" and an average target price of $6.91.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.